May 16th 2025
The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
Treatment for SUI may soon be easier to swallow
January 1st 2002Chicago-A mixed serotonin and noradrenaline reuptake inhibitor appears to reduce the symptoms associated with stress urinary incontinence (SUI) and improve the quality of life in patients receiving it, according to findings from a phase II clinical trial presented at the American Urogynecologic Society 22nd annual scientific meeting here. While the agent, duloxetine, is still investigational, observers say the prospects for a pharmacologic approach to stress incontinence are promising.
Study challenges current WHO male infertility standards
January 1st 2002New York-Recently published data could better help diagnose and select treatments for infertile couples, targeting treatments likely to work and perhaps sparing some patients invasive, high-cost treatments less likely to prove effective.
Androgen suppression raises fracture risk five-fold
December 1st 2001Cleveland-Although skeletal fractures attributed to androgen suppressionare present in a small percentage of men on the therapy, the incidence maybe as high as five times that of the normal population, according to VincentS. Ricchiuti, MD, chief resident, department of urology, Case Western Reserve-UniversityHospitals, Cleveland.
Watch for alternative med use in infertile patients
December 1st 2001Toronto-Not unlike many of the patients seen in urology practices, a significant percentage of young infertile men take alternative therapies, some of which may adversely affect their fertility. But many of these men may be hesitant to share this information with you.
Chronic prostatitis symptoms stabilize over time
November 1st 2001Boston-Perhaps offering a measure of reassurance to prostatitis patientsand their urologists, data from a prospective study suggest that the symptomsof chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) typicallyimprove or remain stable over time. During a 1-year follow-up of a cohort receiving "usual care"for their symptoms, half the patients had symptom improvement, and morethan one-third reported their symptoms unchanged. Symptoms deterioratedin about 14% of patients.
Infertility found to be risk factor for bone loss
November 1st 2001New York-The young, otherwise healthy men urologists see for an infertility evaluation may be hiding a condition more commonly observed in older men and women. Researchers from the Cornell Institute of Reproductive Medicine in New York report that three-fourths of men with nonobstructive azoospermia, a severe form of male infertility, are at risk for significant bone loss.
Practice guidelines standardize infertility management
August 1st 2001Baltimore-For the first time, urologists and gynecologists have the basis for a unified approach to the management of male infertility in a series of four practice policies jointly produced by AUA and the American Society for Reproductive Medicine.
Web site offers news about general urology, subspecialties
July 1st 2001Washington-MDLinx now offers www.urologylinx.com, a web site featuring news about general urology and urologic subspecialties. The site's subspecialties include adrenal glands, erectile dysfunction, infertility, kidney, pediatric urology, penis, prostate, stones, testis/scrotum, ureter, urethra, urinary bladder, uroradiology, voiding dysfunction, basic science/genetics, economics of medicine, and popular press.
Studies raise questions about link between HPC2 gene and PCa
July 1st 2001Many prostate cancer researchers were delighted last fall by two significant developments. First, Myriad Genetics, a Salt Lake City-based biopharmaceutical company, announced on October 4 that its research team had cloned a prostate cancer susceptibility gene (HPC2), also known as ELAC2. That same month, an independent research team at the University of Pennsylvania published its findings that the variant allele (copy) of the gene was found to be more common in men with prostate cancer than in healthy matched controls.